{"name":"Kowa Company, Ltd.","slug":"kowa-company-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"K-924 HD","genericName":"K-924 HD","slug":"k-924-hd","indication":"Hypertension","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"K-924 LD","genericName":"K-924 LD","slug":"k-924-ld","indication":"Parkinson's disease","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"NIK-333(peretinoin)","genericName":"NIK-333(peretinoin)","slug":"nik-333-peretinoin","indication":"Hepatocellular carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"K-924 HD","genericName":"K-924 HD","slug":"k-924-hd","phase":"phase_3","mechanism":"K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure.","indications":["Hypertension","Heart failure"],"catalyst":""},{"name":"K-924 LD","genericName":"K-924 LD","slug":"k-924-ld","phase":"phase_3","mechanism":"K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals.","indications":["Parkinson's disease"],"catalyst":""},{"name":"NIK-333(peretinoin)","genericName":"NIK-333(peretinoin)","slug":"nik-333-peretinoin","phase":"phase_3","mechanism":"NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist.","indications":["Hepatocellular carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNeC1xTV9JMmNIcnQ4aHp3NzBVakdyVngxWUZESUx4b2ZRRi1pR3VwVFlxdGVZVEE4dzVDTlptSWhleXMtc0NJdnBvNFMyWXlCak1EMGloXzFhQWFmRm91M3ZfdXlNTHhiQlVxbzNEUmQ5ejdPYXE3djhxZm1aMl95MjFxem1Bbjk3NVZwZVc0ODVOREdNX1RN?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ - openPR.com","headline":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOTU5XV2JzZHdkc0lzTHA0UnRKMzIyRk92WDZKZGdqNDNTelpzeVJRSGxuVHFrQkFiQWRwUGxlUUUwS2stR3hZUVdpelFwMDRPbGVqSHVpV09mX0NUTkhZWW1SRk0zdFhMcGROTnZmbDhRT285Zm81WTBCN2ozeG93eVJoZGF3S1N3ellhRGt4bGd1bklBQTcyRHctOHU1MVFzNHlhRG1ydmdtMmhsR3QxS19STzBFLUEx?oc=5","date":"2026-02-17","type":"regulatory","source":"Eyes On Eyecare","summary":"Nicox reports positive pre-NDA FDA meeting for IOP-lowering drop - Eyes On Eyecare","headline":"Nicox reports positive pre-NDA FDA meeting for IOP-lowering drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQcEE1eEhjMWdkeE1fMnpzNHZSeVBsbXhJdEdrVWhGWldYU2dWM0hJQXhhaEdYeFdkTzZYLVVEZXRiX1dTUFRJM1dPQkoyQUpvdDFFek53Nl9kZldTbXdYeU1xbkxoem4xdE9MUWF6YjZMYXZtNFpfN2Ytak9HLUFDM2VNMUgtNHVSN3BDUm1ld05JaGt6eW1ZUUJkeklaSEdYWGxldg?oc=5","date":"2026-02-08","type":"regulatory","source":"lupin.com","summary":"Lupin receives FDA approval for Nikita™ (Pitavastatin) Tablets - Lupin | Press Release - lupin.com","headline":"Lupin receives FDA approval for Nikita™ (Pitavastatin) Tablets - Lupin | Press Release","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPUVhjSEhpeEtMN1NrSy14VnU2UnQzdnlPeEVONm95N3RtbGdybmM3YlRUM3I4SjJKOWQxR0FQNjRSanQyYXdnTnJSRzI3MkFlaTFBV3lnU2dNc3hmaEFtLUNpRUt6LWNFb21NYkNnQjFWWWVzUE5oVHQtZkRoQXBoWXlwYVVtV2NBMnRZ?oc=5","date":"2025-11-26","type":"regulatory","source":"Future Market Insights","summary":"Demand for Yeast Infection Treatment in Japan | Global Market Analysis Report - 2035 - Future Market Insights","headline":"Demand for Yeast Infection Treatment in Japan | Global Market Analysis Report - 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE91RExBQnVGSGI4OTRWUjJUR0hib1Niek9MSkxsdUJtSjl2d09XNEVPU0VaTVJxVWg3WDlVSXJuQVlKTnpocmtXNUhpLUt6QXpxNVMzY0J5SWdxa1pmVW9sejNLcw?oc=5","date":"2025-10-16","type":"pipeline","source":"Wiley Online Library","summary":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesity care - Wiley Online Library","headline":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPdWd3MTluVC12QmF3MGVUaGhSWnBqLVJwZE13NG9vSm5CN0JkWUNWVWd3M1h5bFl0MFZoZUpFUTR4NXZOcjE2OXVfUjNwX1JHSGRTcE1sNUphanZfTUtZZk5taTdwVUVsMzJjNWZiUjNCaXVhbmY4MEJqdktkTFRFa1ZTaUhIRVFNXzJzRVowcVJFdmtWS1diOUc4WE5PVG5pdTJqSlozNHBjT3c?oc=5","date":"2025-08-19","type":"deal","source":"BioSpectrum Asia","summary":"Nicox and Kowa sign €191.5 M deal for glaucoma treatment - BioSpectrum Asia","headline":"Nicox and Kowa sign €191.5 M deal for glaucoma treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOYWJSVWxJVEZkcTZOeXdBSXc5eVFsRUotUC1QTkl2ZUlMQlpWcDNzRkhILVRmUmstenhUOUNJekJrTjRXakZlMXFQNUhmZUZJVFR5bWs0TnJHdTdSdnl6TWlockxPZmNZcFlHQlZlR2lNRS1KWTh4b0kxTXdxV0pGcUF3alk?oc=5","date":"2025-07-16","type":"deal","source":"Yahoo Finance UK","summary":"Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories - Yahoo Finance UK","headline":"Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxONE80VmdPbjZJU0NDVGc2dnBUcnhmQnU3UHJyYmRvdGkxdXNjWWYwMmxIaVVVV0VycjdrcWNQSk9fS05tMjJPX3JxejI3ZGNvYXNnSEt0dVVJV3VkNTJKVDZ5NDlOU3kyX3lSN1FyN1FfOXNBVURtYlpJempRQ05CT0haRG9ZMDNndFM1QnY1NlRmNFdSSk02WGxpalNaZW9waXRoOUV6elRQSjdMYThzdnBUaENqOTJxa0xTdHhHaElqRHNoWHFqTjNYMFVJQUQ4MDdhcHBSLXRzWlRvbVdvZllIa2Q0Mm1DcHdRLTY2Wkw?oc=5","date":"2024-07-29","type":"pipeline","source":"GlobeNewswire","summary":"Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. - GlobeNewswire","headline":"Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-04-08","type":"deal","source":"MLB.com","summary":"Los Angeles Dodgers and Kowa announce multi-year partnership - MLB.com","headline":"Los Angeles Dodgers and Kowa announce multi-year partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNQ0Q2dHF5U3pDQTAxcTdqckQ0aXUxTUlYOXhIZ2tJcEN6NThpUWxYX2tZbzJwaGJwVWw0U21haENOdXN6a2RBQUxlNk42ajlRSXlXTnlMVlItMTFSWWpaNTB2SWZDUnEyOUhTbXNUcG9jTklZY1FHVTBYak43T1NVWVlRMHBLUTd2bmZJRzV6NnhVa2xuZElJYWNJXzdhMXdsc3lvY3dMUjhwRnVxX0RWd1NCaGNRM3pNeVBfdmQzZFM5eWhILVdpMjN3MmdLZmQtZGg3bmVYOVg?oc=5","date":"2022-01-31","type":"pipeline","source":"Reuters","summary":"Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says - Reuters","headline":"Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMDc1MHo0MDVzRnh5NF9hZUhxSnU0NXVPZ2d1OGVsYVA1VXFORTV2bUFaU0RLUHZzWEU4Y2VUTlVHRGJzb1JVSkVoZkVSU3VZMXJoRDRXRVB0X3A0cDRoT1YtM2xTUlFONXplMnUyMmxoUXp0djRfQldhNnBnSERpa00wNW4zNHlCNXpvNG9aaHdheS1qU19HTXVpTDkyenFBZ2Z3dXd2NVA1VGpxOWU0dVVUNUlmR3Ji?oc=5","date":"2018-04-07","type":"pipeline","source":"Eli Lilly","summary":"Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement - Eli Lilly","headline":"Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}